106.99USD+0.88%Mkt Cap: —P/E: 35.681d ago
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value13.68B $
Revenue (TTM)1.66B $
Gross Profit1.27B $
Net Income (TTM)413.60M $
Revenue/Share14.15 USD
Last Price106.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees423
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS40637H1095
Valuation
P/E (Trailing)35.68
P/E (Forward)—
PEG—
EV/EBITDA13.02
EV/Revenue8.22
P/S—
P/B83.36
EPS (TTM)3.00
EPS (Forward)—
52W Range
102.1679% of range108.25
52W High108.25 USD
52W Low102.16 USD
Profitability
Gross Margin76.27%
Oper. Margin59.80%
EBITDA Margin63.15%
Profit Margin24.86%
ROE173.67%
ROA25.49%
Growth
Revenue Growth47.70%
Earnings Growth42.90%
Cash Flow & Leverage
Operating CF818.60M $
CapEx (TTM)—
FCF Margin20.27%
FCF Yield—
Net Debt1.95B $
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity1517.69
Current Ratio2.71
Quick Ratio1.99
Book Value/Sh1.259 USD
Cash/Share2.035 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.143.95M
Float112.17M
Insiders1.11%
Institutions112.37%
Technical
SMA 5036.88 (+190.1%)
SMA 20037.43 (+185.8%)
Beta0.85
S&P 52W Chg20.80%
Avg Vol (30d)499
Avg Vol (10d)452
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—